Tornado Therapeutics is a pipeline company of Cambrian Biopharma, established to develop safer, more effective mTOR inhibitors.

The company is currently working on structural analogues of rapamycin with novel selectivity profiles that are predicted to improve safety and efficacy. The lead compound is now moving into IND enabling studies, while a second asset is undergoing preclinical efficacy testing.